Clinical Trial Update: A Multicenter Trial to Investigate Fesoterodine Sustained Release in Overactive Bladder Syndrome [Phase 3]

View source ↗

Summary

A multicenter Phase 3 trial evaluating fesoterodine sustained release for overactive bladder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Overactive Bladder

Drugs mentioned

• Fesoterodine (fesoterodine)

Snippet

Sponsor: Pfizer | Conditions: Overactive Bladder Syndrome | Phase 3 | Status: COMPLETED